

Curriculum vitae

Date Prepared: September 19, 2011
Last Updated: February 9, 2012

Name: Darren Keith McGuire, MD, MHSc, FAHA, FACC

Office Address: University of Texas Southwestern Medical Center
5323 Harry Hines Boulevard
St. Paul Hospital, Suite HA9.133
Dallas, TX 75390-9047

Work Phone: 214-645-7500

Work E-Mail: Darren.McGuire@utsouthwestern.edu

Work Fax: 214-645-7501

Place of Birth: Fayetteville, Arkansas

Education

Year	Degrees (Honors)	Field of Study	Institution
1998-2000	MHSc	Clinical Research Training Program	Duke University School of Medicine, Durham, North Carolina
1989-1993	M.D.; (Alpha Omega Alpha)	Medicine	Johns Hopkins University School of Medicine, Baltimore, Maryland
1985-1989	B.A.; (Honors; Distinction; summa cum laude)	Chemistry	Hendrix College, Conway, Arkansas

Postdoctoral Training

Year(s)	Titles	Specialty/Discipline	Institution
1997-2001	Cardiology Fellowship	Cardiology	Duke University, Durham, NC
1996-1997	Cardiology Research Fellowship	Human Physiology Lab Mentor: Dr. Jere H. Mitchell	UT Southwestern, Dallas, Texas
1993-1996	Intern/Resident	Internal Medicine	UT Southwestern, Dallas, Texas

Current Licensure and Certification

Licensure
Texas

Board and Other Certification

1996-2006 Board Certification Internal Medicine

2002-present Board Certification – Cardiovascular Medicine

Honors and Awards

Year	Name of Honor/Award	Awarding Organization
2011	Dallas Heart Ball Chair for Research on Heart Disease in Women	UT Southwestern Foundation
2011	Internal Medicine House Staff Outstanding Research Mentor Award	UT Southwestern
2008, 2010	Top Reviewer Citation	Annals of Internal Medicine
2008	Odyssey Award in Research	Hendrix College, Conway, AR
2008	Class of 2008 Core Clerkship Teaching Award-Acute Care	UT Southwestern
2006	Alumni Hall of Honor	Mountain Home High School, Mountain Home, AR
2006	Internal Medicine Residency Program- Excellence in Teaching Award	UT Southwestern
2005-2008	Alumni Board of Governors	Hendrix College, Conway, AR
2000-2001	Outstanding Clinical Research Fellow	Duke University Cardiology
1999-2000	Chief Fellow	Duke Clinical Research Institute
1993-present	Alpha Omega Alpha Medical Honor Society	Johns Hopkins University School of Medicine
1989	<i>Summa cum laude</i> with Honors and Distinction in Chemistry	Hendrix College
1988	Rhode's Scholarship Finalist	Arkansas Nominee
1987-1989	Arkansas National Advisory Board	State of Arkansas

	Scholar	
1985-1989	Arkansas Governor's Scholar	State of Arkansas

Faculty Academic Appointments

Year(s)	Academic Title	Department	Academic Institution
2001-2006	Assistant Professor	Internal Medicine-Cardiology	UT Southwestern
2006-Present	Associate Professor	Internal Medicine-Cardiology	UT Southwestern
2007-Present	Adjunct Faculty, Ethics Division	Department of Clinical Sciences	UT Southwestern

Appointments at Hospitals/Affiliated Institutions

<u>Past</u>			
Year(s)	Position Title	Department/Division	Institution
2001-2009	Staff Physician	Internal Medicine/Cardiology	Dallas VA Medical Center
<u>Current</u>			
Year(s)	Position Title	Department/Division	Institution
2001-Present	Staff Physician	Internal Medicine/Cardiology	Parkland Memorial Hospital
2001-Present	Staff Physician	Internal Medicine/Cardiology	University Hospital-St Paul
2001-Present	Staff Physician	Internal Medicine/Cardiology	University Hospital-Zale Lipshy

Other Professional Positions

Year(s)	Position Title	Institution
2009-Present	Member	US FDA Center for Drug Evaluation and Research, Cardiovascular and Renal Drug Advisory Committee
2001-Present	Lead Physician, Outpatient Cardiology Clinics	Parkland Hospital and Health System
2001-2010	Associate	Donald W. Reynolds Cardiovascular Clinical Research Center at UT Southwestern

Major Administrative/Leadership Positions

Year(s)	Position Title	Institution
2010-Present	Director	UT Southwestern Cardiology Clinical Research Unit
2005-2008	Associate Program Director, Internal Medicine Training Program	UT Southwestern
2001-2010	Co-director	UT Southwestern Cardiology Clinical Research Unit

Committee Service

Year(s)	Name of Committee	Institution/Organization
<u>UTSW</u>		
2011-Present	Internal Medicine Faculty Mentor Committee Ramin Farzeneh-Far Anand Rohatgi	UT Southwestern
2010-Present	Clinical Research Infrastructure Committee	UT Southwestern
2009-Present	Wellness Advisory Committee	UT Southwestern
2009-2010	President's Task Force on Health Policy and Health Services Research	UT Southwestern
2008-2009	Continuing Education Advisory Committee	UT Southwestern
2006-Present	Institutional Review Board #4	UT Southwestern
2004-2006	Institutional Review Board Executive Committee	UT Southwestern
2004-2006	Chair, Institutional Review Board #4	UT Southwestern
2004	Ad hoc Chair, Institutional Review Board #3	UT Southwestern
2003-2004	Institutional Review Board #3	UT Southwestern
<u>Hospital</u>		
2011-Present	Parkland Executive Research Committee	Parkland Hospital and Health System
2011-Present	University Hospitals Clinical Research Committee	UT Southwestern
2009-Present	Cardiology High Performance Committee	Parkland Hospital and Health System

Professional Societies

Dates	Society
1996-Present	American Heart Association
1997-Present	American College of Cardiology
2001-Present	American Diabetes Association
2003-2009	National Lipid Association

	Fellowships	
2008	American Heart Association	
2008	National Lipid Association	
2003	American College of Cardiology	
	Committees	
2011-Present	Statistics Committee Member	American Heart Association Council on Epidemiology and Prevention
2011-Present	American Heart Association Liaison	The Endocrine Society Task Force for Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk
2010-Present	Writing Committee, “Type 1 Diabetes and Cardiovascular Risk” Scientific Update	American Heart Association
2010-2011	Strategic Planning Subject Matter Expert Group	American Diabetes Association
2009-2011	Diabetes Council Advisory Group	American Association of Clinical Endocrinologists
2009-2011	Executive Leadership Committee	American Heart Association Council on Nutrition, Physical Activity and Metabolism (NPAM)
2009-2011	Chair	American Heart Association Diabetes Committee
2009-2011	Member	American Heart Association Council on Nutrition, Physical Activity, and Metabolism Nominating Committee
2009-Present	National Spokespersons Panel	American Heart Association
2008-Present	Nutrition, Physical Activity, and Metabolism Council Program Planning Committee	American Heart Association Annual Scientific Sessions
2008-Present	Abstract Grader	American Heart Association Annual Epi/NPAM Joint Conference
2008-2011	Co-Chair	American College of Cardiology “Cardiovascular Disease in Type 2 Diabetes Mellitus” national education initiative
2008	AHA Liaison and Writing Committee member	American College of Endocrinology/American Association of Clinical Endocrinologists Consensus on PreDiabetes

2008-Present	Scientific Sessions Planning Committee, Session Builder, “Diabetes and CVD”	American Heart Association
2007-2009	Executive Leadership Committee (Early Career Investigator)	American Heart Association Council on Nutrition, Physical Activity, and Metabolism (NPAM)
2007-2009	Vice Chair	American Heart Association Diabetes Committee
2007-Present	Abstract grader	American Diabetes Association Annual Scientific Sessions
2006-Present	Diabetes Committee	American Heart Association
2006-2009	Faculty	American College of Cardiology Foundation Annual Board Review Course
2006-2008	Board of Directors	Southwest Lipid Association
2004-Present	Faculty	American Heart Association Scientific Sessions
2004-Present	Faculty	American College of Cardiology Scientific Sessions
2003-Present	Abstract Grader	American Heart Association Annual Scientific Sessions
2003-Present	Abstract Grader	American College of Cardiology Annual Scientific Sessions

Editorial Activities

Year(s)	Journal Name
<u>Editor/Associate Editor</u>	
2010-Present	Journal of the American College of Cardiology- <i>Ad hoc</i> Guest Editor
2007-Present	American Heart Journal, Associate Editor
2007-Present	Diabetes & Vascular Disease Research, Senior Associate Editor
2003-2007	Diabetes & Vascular Disease Research, Associate Editor
2008	Obesity, Associate Editor
2003-2007	American Heart Journal, Ad hoc Guest Editor
<u>Editorial Board</u>	
2006-Present	The American Journal of Cardiology
2003-Present	Diabetes & Vascular Disease Research
2001-Present	American Heart Journal
2008	Obesity
2005-2008	Journal of the Cardiometabolic Syndrome

<u>Ad Hoc Reviewer</u>	
2011-Present	Cardiovascular Diabetology; Heart Rhythm Journal; Journal of the American Heart Association
2010-Present	European Journal of Heart Failure; Journal of Clinical Endocrinology & Metabolism
2009-Present	Circulation: Cardiovascular Quality and Outcomes; Clinical Biochemistry; Pharmacoepidemiology and Drug Safety; Clinica Chimica Acta; Nature Reviews Cardiology
2008-Present	Nature Clinical Practice Endocrinology and Metabolism; Journal of Internal Medicine; Clinical Pathways in Cardiology; Circulation: Cardiovascular Interventions
2007-Present	AHA Position Statements
2007-Present	Obesity; Atherosclerosis; JAMA, International Journal of Cardiology
2006-Present	Heart and Vessels; Journal of Invasive Cardiology; Journal of the American College of Cardiology; PLoS Medicine
2005-Present	Specialty Consultants Panel, Prescriber's Letter/Pharmacist's Letter
2005-Present	Annals of Internal Medicine; Drugs; Diabetologia; Diabetic Medicine; The British Journal of Diabetes & Vascular Disease
2004-Present	Journal of Alternative and Complementary Medicine; Diabetes & Vascular Disease Research; Archives of Internal Medicine; Journal of Investigative Medicine; Journal of Diabetes and Its Complications
2003-Present	European Heart Journal
2002-Present	American Journal of Physiology; Circulation
1997-Present	American Heart Journal; Diabetes Care

Grant Support

<u>Past</u>	<i>Grantor:</i> Pfizer pharmaceuticals
10/1/1999-6/30/2004	<i>Title of Project:</i> Post-Acute Coronary Events-Therapy (PACE-Rx) Study
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> Award amount: \$60,000 (unrestricted educational grant)
	Broad Goal: To evaluate the effectiveness of an algorithm-based disease management strategy applied by physician-extenders in the evidence-based management of patients following acute coronary syndromes
10/1/1999-9/30/2006	<i>Grantor:</i> Donald W. Reynolds Foundation
	<i>Title of Project:</i> Donald W. Reynolds Cardiovascular Clinical Research Center
	<i>Role (Principal Investigator, Co-Investigator):</i> Associate

	<i>Annual amount and date (direct costs only):</i> Current Year Annual Award Amount: \$3,942,923 (direct costs)
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	Broad Goal: To develop new measures that reduce death and disability from atherosclerotic heart disease and its major complications. Salary Support: \$45,000 (salary) + fringes
	<i>Grantor: GlaxoSmithKline</i>
10/1/2004-4/1/2006	<i>Title of Project:</i> Effects of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> 499,864
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	Broad Goal: To assess the effects of the thiazolidinedione medication, rosiglitazone versus placebo on parameters of cardiovascular performance, cardiac structure and function, and myocardial triglyceride content in a 4-center randomized controlled trial.
10/01/2004-4/01/2006	<i>Grantor:</i> Donald W. Reynolds Foundation
	<i>Title of Project:</i> Effects of Rosiglitazone versus Placebo on Cardiovascular Performance and Myocardial Triglyceride
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> Award Amount: \$100,000
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> Award Amount: \$100,000
	Broad Goal: To assess the effects of the thiazolidinedione medication, rosiglitazone versus placebo on parameters of cardiovascular performance, cardiac structure and function, and myocardial triglyceride content in a 4-center randomized controlled trial.
10/01-2004-4/01-2006	<i>Grantor:</i> Biosite, Inc
	<i>Title of Project:</i> Effects of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride

	<i>Role (Principal Investigator, Co-Investigator): Principal Investigator</i>
	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only): 50,000</i>
	Broad Goal: To assess the effects of the thiazolidinedione medication, rosiglitazone versus placebo on parameters of cardiovascular performance, cardiac structure and function, and myocardial triglyceride content in a 4-center randomized controlled trial.
12/2005-12/2006	<i>Grantor:</i> UT Southwestern Medical Center President's Fund
	<i>Title of Project:</i> Dallas Bedrest and Training Study Follow-up
	<i>Role (Principal Investigator, Co-Investigator): Principal Investigator</i>
	<i>Annual amount and date (direct costs only):</i> Award amount: \$34,000 (unrestricted educational grant)
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	Broad Goal: To assess the cardiovascular effects of aging in a longitudinal study of 5 men, now 40 years in duration.
7/1/2006-6/30/2007	<i>Grantor:</i> ACCF/Merck Fellowship
	<i>Title of Project:</i> Assessment of sRAGE in the Dallas Heart Study
	<i>Role (Principal Investigator, Co-Investigator):</i> PI/mentor: Jason Lindsey/Darren K. McGuire
	<i>Annual amount and date (direct costs only):</i> Award amount: \$60,000 (research fellow stipend support)
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	Broad Goal: To assess the associations between atherosclerosis and circulating soluble receptor for advanced glycation end-products (sRAGE)

Clinical Trials Activities

Trial Leadership	
2011-Present	Executive Committee, STRENGTH international randomized trial
2011-Present	Executive Committee, Takeda-875-306 international randomized trial

2011-Present	Executive Committee, CARMELINA international randomized trial
2011-Present	Data Safety Monitoring Committee, CONTRAVE cardiovascular outcome trial
2010-Present	Executive Committee, PREVAIL National Quality Initiative
2009-2011	Executive Steering Committee, T-EMERGE 8 international randomized trial
2009-Present	Steering Committee, SAVOR international randomized trial
2009-Present	Director, Cardiovascular Event Adjudications, colesevelam registration program
2009-Present	Steering Committee, US National Coordinator, ALECARDIO international randomized trial
2008-2011	Chair, Data Safety Monitoring Committee, randomized trial of exenatide in the CCU setting
2008-Present	Executive Committee, TECOS international randomized trial
2008-2009	Clinical Events Adjudication Committee, PLATO international randomized trial
2007-Present	Steering Committee, TRILOGY international randomized trial
2005-Present	Steering Committee, IMPROVE IT international randomized trial
2003-2005	Steering Committee, Takeda Study 504 (PURE 2) international randomized trial
1999-2005	Steering Committee, Estudios Cardiologica Latinoamericas (ECLA) Glucose-Insulin-Potassium (GIK) II international randomized trial
1999-2000	Steering Committee BARI 2D randomized trial
<u>Site Investigator</u>	
Present	
<u>Principal Investigator</u>	<i>Trial</i>
2008-Present	TECOS international randomized trial
	ORIGIN international randomized trial
SubInvestigator	SAVOR-TIMI 53 international randomized trial
	IMPROVE-IT international randomized trial
	ENGAGE international randomized trial
	ROCKET international randomized trial
	TRA-2P international randomized trial
	TRACER international randomized trial
	VIRGO acute coronary syndrome registry

	EXCSEL international randomized trial
Past	
Principal Investigator	
2005-2009	TRILOGY study international randomized trial
2006-2009	CRESCENDO international randomized trial
2005-2009	TRIUMPH acute coronary syndrome registry
2005-2008	JUPITER international randomized trial
2003-2006	Pom-Wonderful randomized trial
2003-2004	Takeda Study 504 (PURE 2) international randomized trial
2002-2007	DREAM international randomized trial
2002-2008	TRANSCEND international randomized trial
2002-2007	ONTARGET international randomized trial
2001-2004	Estudios Cardiologica Latinoamericas (ECLA) Glucose-Insulin-Potassium (GIK) II international randomized trial
SubInvestigator	
2001-2004	Co-Investigator-Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) Trial
1999-2000	Co-Investigator BARI 2D Trial; Duke University Medical Center

Teaching Activities

Year(s)	Activity	
2009-Present	Faculty	UT Southwestern Preventive Cardiology Lecture Series
2007-Present	Trial Design-Power and Sample Size Considerations	Didactic Lecture Series for UT Southwestern Cardiology Fellowship
2007-2008	<i>Ad hoc</i> Faculty, Internal Medicine Morning Report	Dallas VA Medical Center
2007-2010	Faculty, Internal Medicine Residents Annual Board Review	UT Southwestern
2006-Present	<i>Ad hoc</i> Lecturer, Department of Clinical Sciences Ethics in Clinical Science	UT Southwestern

	Curriculum	
2004	Co-Chair	Type 2 Diabetes, The Metabolic Syndrome and Obesity: Evolving the Paradigms, January 29-31; Tysons Corner, Virginia
2004-Present	Mentor; UTSW Medical Student Summer Research Program	UT Southwestern Medical Center
2004-Present	Clinical Research Seminar for Summer Research Interns at UT Southwestern Medical Center: "Introduction to Statistics"	UT Southwestern Medical Center
2003-2010	Co-Chair	Annual Diabetes Summit Satellite CME Symposium at the American Heart Association Scientific Sessions
2003-Present	Lecture Series for UT Southwestern Internal Medicine Housestaff: Reading and Interpreting Medical Literature	UT Southwestern Medical Center
2003-2005	Faculty, UT-Southwestern School of Allied Health Sciences "Health Care Research" course	UT Southwestern Medical Center
2002-2006	Faculty	UT-Southwestern School of Allied Health Sciences-Physical Therapy Course on Pathophysiology
2002-Present	Division of Cardiology, Didactic Lecture Series for Fellows "Diabetes and Cardiovascular Disease Introduction to Statistics"	UT Southwestern Medical Center
2002-2006	Faculty,	UT-Southwestern School of Allied Health Sciences-Physician Assistant Course on Clinical Pharmacology
2001-2006	Faculty	Internal Medicine Subinterns' Morning Report
2001-2005	Faculty	UT Southwestern Medical School "Clinical Ethics in Medicine" course
2001-Present	Co-Director	UT Southwestern Internal Medicine Residency Journal Club
	Mentoring	
2010-Present	M. Odette Gore, MD	UT Southwestern Medical Center
2010-2011	Nikhil Narang, MS, Doris Duke Fellow	UT Southwestern Medical Center
2001-2006	Co-mentor, Anne-Marie Svensson; PhD	University of Goteborg, Goteborg, Sweden
2005-2009	Jason B. Lindsey, MD	UT Southwestern Medical Center
2004-2006	Amit Khera, MD	UT Southwestern Medical Center

Invited Lectures

Year(s)	Title	Location
International		
2011	2 nd Annual International Conference on Abdominal Obesity: “Lifestyle versus Medications for Treatment of Cardiovascular Risk in Diabetes”	Buenos Aires, Argentina
2009	15 th Annual Symposium on New Concepts in Acute Coronary Syndromes: Beyond 2000: “Focus on Diabetes: threats and opportunities in acute coronary disease”, October 25	Edmonton, Alberta, CA
2007	3rd Annual Russell Ross Cardiovascular Symposium: "Epidemiology of Diabetes, Insulin Resistance, and Acute Coronary Syndromes", Ulm, Germany June 29	Ulm, Germany
2002	Herzcentrum Ludwigshafen, Ludwigshafen Germany Division of Cardiology Grand Rounds: “Reducing cardiovascular risk among patients with diabetes.” August 27	Ludwigshafen, Germany
National		
2011	ACCF New York Cardiovascular Symposium, “Diabetes and Evolving Approaches: What are the contemporary targets and how to achieve them?” December 9	New York, NY
2011	Medscape Cardiology Education series, “Getting to the Heart of the Matter: The Role of the Cardiologist in Managing Type 2 Diabetes”, December 9	Orlando, FL
2011	Cardiometabolic Health Conference, “ACS in Patients with T2DM: Obstacles to Primary and Secondary Prevention”, October 19	Boston, MA
2011	AHA Scientific Sessions Sunday Morning Program: “Regulation of Diabetes Drugs” November 13	Orlando, FL
2011	Hartford Hospital Annual Cardiovascular Symposium, “Cardiovascular Considerations of Chronic and Acute Glucose Management in Type 2 Diabetes”, October 5	Hartford, CT
2011	Thomas Jefferson University, The 22 nd Annual Edna G. Kynett Memorial Foundation Symposium, “A Spoonful of Medicine Helps the Sugar Go Down: Cardiovascular considerations in type 2 diabetes” April 14	Philadelphia, PA
2011	ACCF West Coast Cardiovascular Forum, “A Spoonful of Medicine Helps the Sugar Go Down: Cardiovascular considerations in type 2 diabetes”, March 28	San Francisco, CA
2010	ACC Williamsburg Annual Cardiovascular CME Conference,	Williamsburg, VA

	“Controversies in the Management of Diabetic Cardiovascular Disease”, December 11	
2010	World Congress on Insulin Resistance, “Insulin, Glucose, and Acute Coronary Syndromes: A spoonful of medicine helps the sugar go down”, November 5	Los Angeles, CA
2010	Duke Clinical Medicine Series 2010, “Glucose Management in Cardiovascular Disease: A spoonful of medicine helps the sugar go down.” July 14	Asheville, NC
2010	Cardiology Grand Rounds, Columbia University: “Insulin, Glucose, and Acute Coronary Syndromes: A spoonful of medicine helps the sugar go down.” May 11	New York, NY
2010	US Congressional Caucus on Diabetes: “Diabetes Risk Prediction and Risk Prevention”, February 26.	Washington, DC
2010	Cardiology/Endocrinology Combined Grand Rounds, Duke University Medical Center: “Insulin, Glucose, and Acute Coronary Syndromes: Update on the Evidence” February 1	Durham, NC
2010	Cardiology Grand Rounds, University of Colorado Health Sciences Center: “Insulin, Glucose, and Acute Coronary Syndromes: Update on the Evidence” January 22.	Denver, CO
2009	7 th World Congress on Insulin Resistance: “Glucose control and cardiovascular considerations: Resolving Fallacy, Faith, and Fact”, November 5.	San Francisco, CA
2009	Faculty, CardioMetabolic Health Congress: “Clinical Strategies for Diabetes Prevention in Patients with Pre-Diabetes: How Can We Do Better?” October 9	Boston, MA
2009	New York University Annual Symposium-Cardiovascular Risk: Lipids and Beyond: “Diabetes and Cardiovascular Disease”, May 15	New York, NY
2009	5 th Annual Biomarkers in Heart Disease Symposium: “Assessing Cardiometabolic Risk”, April 25	San Diego, CA
2009	Brigham and Women’s Hospital Division of Cardiology Grand Rounds: “Insulin, Glucose, and ACS: Update on the Evidence”, April 16.	Boston, MA
2009	TIMI Study Group Grand Rounds: “Cardiovascular Safety Assessment of Diabetes Medications”; April 16.	Boston, MA
2009	University of Texas Houston Division of Cardiology Grand Rounds: “Insulin, Glucose, and ACS: Update on the Evidence”, April 9.	Houston, TX
2009	American College of Cardiology Annual Scientific Sessions, Orlando, FL March 28-31 “Importance of Glucose Control in Diabetic Patients with Vascular Disease,” Plenary Session	Orlando, FL

	<p>“Glycemic Control: Lower is not Better,” Special Session “Should the Mainstay of Therapy be an Insulin-providing or an Insulin-sensitizing Strategy?”, ACC.Symposium “The Convergence of Type 2 Diabetes and Cardiovascular Disease”, Meet the Experts “Diabetes and Cardiovascular Disease”, ACC.Core Curriculum</p>	
2009	<p>Cardiovascular Conference at Beaver Creek International CME Program, February 11 “Insulin, Glucose, and Acute Coronary Syndromes” & “Thiazolidinediones and Cardiovascular Disease”</p>	Beaver Creek, CO
2008	<p>ACC Williamsburg Annual Cardiovascular CME Conference, “Controversies in the Management of Diabetic Cardiovascular Disease”, December 12</p>	Williamsburg, VA
2008	<p>American Heart Association Scientific Sessions</p> <ul style="list-style-type: none"> • Plenary Session-ACS 2008: Year in Review: “Weight, Smoking, LDL, and Diabetes-Update on the Targets”, November 12, New Orleans <p>Glucose, Insulin and Acute Coronary Syndromes Special Session: “Lessons learned from clinical trials” American Heart Association Scientific Sessions, November 11</p>	New Orleans, LA
2008	<p>Cardiology Grand Rounds, University of Tennessee-Memphis, “Controversies in Diabetes and Cardiovascular Disease: Update on the evidence” August 19</p>	Memphis, TN
2008	<p>Cardiology Grand Rounds, Henry Ford Hospital, “Controversies in Diabetes and Cardiovascular Disease: Update on the evidence” August 12</p>	Detroit, MI
2008	<p>American College of Cardiology Scientific Sessions, Clinical Session: “Optimizing Therapy in the Diabetic Patient”, March 31.</p>	Chicago, IL
2007	<p>40th Annual New York Cardiovascular Symposium: Major Topics in Cardiology Today; “Diabetes: Are cardiologists ready to manage; if not, who is the manager?” Dec 7.</p>	New York
2007	<p>American Heart Association Scientific Sessions: “Diabetes and Cardiovascular Disease: What are the treatment goals in 2007” November 6</p>	Orlando, FL
2007	<p>University of Tennessee-Memphis Endocrinology Grand Rounds; “Thiazolidinediones and Cardiovascular Disease: Update on the Evidence” Oct 4.</p>	Memphis, TN
2007	<p>Co-chair, "Regulation of drugs for the treatment of diabetes: Beyond Hemoglobin A1c?"; June 14-15</p>	Washington, DC
2007	<p>National Lipid Association Annual Scientific Sessions, "Reducing Cardiovascular Risk in Patients with Diabetes", June 2</p>	Scottsdale, AZ
2006	<p>University of Alabama-Birmingham Endocrinology Grand Rounds, "Cardiovascular Considerations of the Thiazolidinediones: Update on the Evidence", November 30</p>	Birmingham, AL

2006	The ACCF Cardiovascular Board Review, "Diabetes/Metabolic Syndrome"; September 10	Las Vegas, NV
2006	Emory University Cardiology Grand Rounds, "Cardiovascular Considerations of the Thiazolidinediones: Update on the Evidence" April 27	Atlanta, GA
2006	Chair, American College of Cardiology Symposium on Metabolic Management of the Patient with Ischemic Heart Disease: Diabetes and the Metabolic Syndrome, March 13	Atlanta, GA
2006	Southwest Lipid Association Inaugural Scientific Session, "Treating HDL Cholesterol: Present and Future Directions" February 11	San Antonio, TX
2005	World Congress on the Insulin Resistance Syndrome, "Cardiovascular Consequences of Diabetes: An epidemiologic overview", San Francisco, California, November 18	San Francisco, CA
2005	Oklahoma University Health Science Center Internal Medicine Grand Rounds, "Cardiovascular Considerations of the Thiazolidinediones", October 19	Oklahoma City, OK
2005	Duke University Medical Center joint Cardiology/Endocrinology Grand Rounds; "Diabetes and Cardiovascular Disease: What's the Evidence?" August 15.	Durham, NC
2005	Faculty, Emory University ESCAPE CME Program; June 13.	Amelia Island, FL
2005	"Diabetes and Cardiovascular Disease: What is the Evidence?", Oklahoma University Health Science Center Cardiology Grand Rounds, April 29.	Oklahoma City, OK
2005	"Metabolic Syndrome: Can Biomarkers Help?", UCSD Symposium on Biomarkers in Heart Disease, La Jolla, CA, March 26.	La Jolla, CA
2005	"The Diabetic Patient with Multivessel Coronary Disease", Am Coll Cardiol Annual Scientific Sessions, March 9.	Atlanta, GA
2004	Transcatheter Cardiovascular Therapeutics "The Diabetic Epidemic: Epidemiologic and therapeutic implications for the interventional cardiologist." "Pharmacologic modification of cardiovascular risk in diabetes: Glucose control and beyond." September 27	Washington, DC
2004	"Emerging Markers of Atherogenic Risk-The Old and the New: Lipid Markers"; American College of Cardiology 53rd Annual Scientific Sessions, March 10	New Orleans, LA
2002	2 nd Annual Diabetes Summit: Linking Science to Medicine: "Type 2 Diabetes Mellitus: The Modern-day Pandemic", November 16	Atlanta, GA
2002	Faculty, The Metabolic Syndrome of Cardiovascular Risk and Insulin Resistance, Washington, DC; April 18-20	Washington, DC
1999	Faculty, Diabetes Update '99, May 3-5; Indiana University: "Diabetes and Cardiovascular Disease"	Indianapolis, IN

Regional/Local		
2011	UT Southwestern Department of Clinical Sciences Distinguished Professor Series, "Regulation of Drugs that Regulate Glucose: Status of Oral Diabetes Drugs" September 1	Dallas, TX
2011	UT Southwestern Division of General Internal Medicine Grand Rounds, "A Spoonful of Medicine Helps the Sugar Go Down: Cardiovascular considerations in type 2 diabetes", February 17	Dallas, TX
2010	Internal Medicine Grand Rounds, UT Southwestern Medical Center at Dallas: "Insulin, Glucose, and Acute Coronary Syndromes: A spoonful of medicine helps the sugar go down." April 9.	Dallas, Texas
2008	UT Southwestern CME Program, Diabetes Management: Challenges to Individualizing Care: "Metabolic Syndrome and Diabetes: Cardiovascular Considerations", November 21	Dallas, TX
2008	UT Southwestern Update in Internal Medicine, "Treating Diabetes: Getting to the Heart of the Matter", Dallas, TX October 29	Dallas, TX
2008	Cardiology Grand Rounds, Baylor University Medical Center, "Controversies in Diabetes and Cardiovascular Disease: Update on the evidence", Dallas, TX June 20	Dallas, TX
2008	UT Southwestern Cardiology Clinical Conference: "Glucose and Insulin in ACS/AMI: Update on the Evidence"; March 20.	Dallas, TX
2008	Methodist Hospital Dallas Internal Medicine Grand Rounds: "Controversies in Diabetes and Cardiovascular Disease: Update on the evidence," February 1.	Dallas, TX
2007	Course Director, UT Southwestern Medical Center 7th Annual Cardiovascular Research Symposium: "Diabetes and Cardiovascular Disease: Making the Link". October 22-23; Dallas, TX	Dallas, TX
2006	American Diabetes Annual Walk Kick-off Breakfast, Keynote speaker "Making the Link: Diabetes and Cardiovascular Disease" September 7	Dallas, TX
2005	University of Texas Southwestern Medical Center Internal Medicine Grand Rounds, "Cardiovascular Considerations of the Thiazolidinediones: Update on the Evidence", November 10.	Dallas, TX
2005	"Diabetes and Cardiovascular Disease: What is the Evidence?", Methodist Hospital Dallas Internal Medicine Grand Rounds, May 20.	Dallas, TX
2005	"IRB Committee Management and Maintenance", UT Southwestern Medical Center Symposium on IRB Best Practices, May 11-12	Dallas, TX
2005	"Diabetes and Cardiovascular Disease: What's the Evidence?", Internal Medicine Grand Rounds, Presbyterian Hospital January 12.	Dallas, TX
2004	University of Texas Annual Chancellor's Council Meeting: "Emerging Concepts of Lipid Therapy: How low can we go?" April	Austin, TX

	30.	
2004	"Glucose and Insulin in Acute MI: Where are we now?"; UT Southwestern Medical Center Cardiology Clinical Conference, March 11, 2004.	Dallas, TX
2003	Baylor University Medical Center, Cardiology Grand Rounds: "Thiazolidinediones: Cardiovascular Friend or Foe," August 22.	Dallas, TX
2002	Visiting Lecturer, University of Texas Health Science Center Division of Cardiology: Cardiac Metabolism Seminar- "Thiazolidinediones: Cardiovascular Friend or Foe"; December 19	UT Health Science Center
2002	University of Texas-Southwestern Medical Center Internal Medicine Grand Rounds, Dallas, Texas: "Thiazolidinediones: Cardiovascular friend or foe?" October 3	Dallas, TX
2002	University of Texas-Southwestern Medical Center Donald W. Reynolds Cardiovascular Research Center Works-In-Progress Seminar: "Rules and Regulations of Human Investigation: Learning the Alphabet." July 12	Dallas, TX
2002	University of Texas-Southwestern Medical Center Endocrinology Grand Rounds: "Glucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: What goes around comes around." April 24	Dallas, TX
2001	University of Texas-Southwestern Medical Center Cardiology Grand Rounds: "Glucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: What goes around comes around." December 14	Dallas, TX

Bibliography

Peer-Reviewed Publications

Original Research Articles

1.	Liarakos CD, Maddox RP, Hilscher KA, Bishop JR 3d, McGuire DK, Kopper RA. Determination of secondary structure in the initiation region of ovalbumin mRNA. <i>Nucleic Acids Res</i> 1988; 16: 11249-65.
2.	McGuire DK, Emanuelsson H, Granger CB, Ohman EM, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ, for the GUSTO IIB Investigators. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes: Findings from the GUSTO IIB study. <i>Eur Heart J</i> , 2000; 21:1750-8.
3.	The 2 nd SYMPHONY Investigators. A randomized comparison of sibralfiban plus aspirin, aspirin alone, and sibralfiban alone for prevention of ischemic events after acute coronary syndromes. <i>Circulation</i> 2001; 103:1727-33.
4.	McGuire DK, Levine BD, Williamson JW, Snell PG, Blomqvist CG, Saltin B, Mitchell JH. A

	30-year follow-up of the Dallas bed rest and training study: Effect of age on the cardiovascular response to exercise. <i>Circulation</i> 2001;104:1350-7.
5.	McGuire DK, Levine BD, Williamson JW, Snell PG, Blomqvist CG, Saltin B, Mitchell JH. A 30-year follow-up of the Dallas bed rest and training study: Effect of age on the cardiovascular adaptation to exercise training. <i>Circulation</i> 2001; 104:1358-66.
6.	Labinaz M, Madan M, O'Shea JC, Kilaru R, Chin W, Pieper K, McGuire DK, Saucedo J, Talley JD, Liu H, Kitt MM, Califf RM, Tcheng JE, for the ESPRIT Investigators. One-year Outcomes of Diabetic Patients Following Coronary Stenting: Results from the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) Trial. <i>Am J Cardiol</i> 2002; 90:585-590.
7.	Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, McGuire DK, Moliterno DJ, Verheugt FWA, Weaver WD, Califf RM, for the SYMPHONY and 2 nd SYMPHONY Investigators. Early statin use and outcomes in patients with acute coronary syndromes. <i>JAMA</i> 2002; 287:3087-3095.
8.	McGuire DK, Anstrom KA, Peterson ED. The influence of the BARI NHLBI diabetic clinical alert on practice patterns: Results from the National Cardiovascular Network database. <i>Circulation</i> 2003; 107:1864-1870.
9.	Cheng YJ, Church TS, Kimball TE, Nichaman MZ, Levine BD, McGuire DK, Blair SN. Coronary artery calcium detected by electron beam tomography and its association with coronary heart disease in 17,967 women and men. <i>American Journal of Cardiology</i> 2003; 92:498-503.
10.	McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Hochman JS, Klein W, Weaver WD, Pfisterer M, Dimas A, Corbalan R, Granger CB, Van de Werf F, Topol EJ, Califf RM, for the SYMPHONY and 2 nd SYMPHONY Investigators. Influence of Diabetes Mellitus and Glycemic Control Strategies on Clinical Outcomes After Acute Coronary Syndromes: Findings from the SYMPHONY and 2 ND SYMPHONY Studies. <i>Am Heart J</i> 2004; 147: 246-52.
11.	Jain T, Peshock R, McGuire DK, Willet D, Vega G, Guerra R, Yu Z, Hobbs HH, MD, Grundy SM, and the Dallas Heart Study Investigators. African Americans and Caucasians have a Similar Prevalence of Coronary Calcium as Detected By Electron Beam Computer Tomography. <i>J Am Coll Cardiol</i> 2004; 44: 1011-1017.
12.	Asher CR, Moliterno DJ, Bhapkar MV, McGuire DK, Rao SV, Holmes DR, Newby LK, Bates ER, Topol EJ, for the SYMPHONY and 2 nd SYMPHONY Investigators. Association of race with complications and prognosis following acute coronary syndromes. <i>Am J Cardiol</i> 2004;94:792-794.
13.	Deo R, Khera A, McGuire DK, Murphy S, Pardo Meo Neto J, Morrow DA, de Lemos JA. Association Between Plasma Levels of Monocyte Chemoattractant Protein-1, Traditional Cardiovascular Risk Factors and Subclinical Atherosclerosis. <i>J Am Coll Cardiol</i> , 2004. 1812-1818.

14.	Addo T, Keeley EC, Cigarroa JE, Lange RA, deLemos JA, Dobbins RL, McGuire DK. The Effect of Glucose-Insulin-Potassium Infusion on Plasma Free Fatty Acid Concentrations in the Setting of Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction. <i>Am J Cardiol</i> 2004; 94: 1288-1289.
15.	Svensson AM, Abrahamsson P, McGuire DK, Dellborg M. Influence of Diabetes on Outcome among Unselected Patients with Acute Coronary Events: A 10-year experience with 4341 patients. <i>Scand Cardiovasc J</i> 2004; 38:229-34.
16.	Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Glycometabolic state at admission and during hospitalization: Important Risk Marker of Mortality in Diabetes Patients with Acute Coronary Events: a 10 year experience . <i>European Heart J</i> , 2005; 38: 229-34.
17.	Sánchez CD, Newby LK, McGuire DK, Hasselblad V, Feinglos MN, Ohman EM. Diabetes-related knowledge is not associated with measures of risk factor control or cardiac outcomes in patients with diabetes and acute coronary syndromes. <i>Am J Cardiol</i> 2005; 95: 1290-94.
18.	Sims JB, de Lemos JA, Maewal P, Warner JJ, Peterson GE, McGuire DK. Urinary Tract Infection in Patients with Acute Coronary Syndrome: A Potential Systemic Inflammatory Connection. <i>Am Heart J</i> 2005; 149: 1062-5.
19.	Khera A, McGuire DK, Murphy SA, Stanek G, Das S, Vongpatanasin W, Wians F, Grundy S, de Lemos, JA. Race and Sex Differences in C-reactive Protein Levels. <i>J Am Coll Cardiol</i> , 2005; 46: 464-469.
20.	Eisenstein EL, McGuire DK, Bhapkar MV, Kristinsson A, Hochman JS, Kong DF, Topol EJ, Califf RM, Van de Werf F, Newby LK, for the SYMPHONY and 2 nd SYMPHONY Investigators. Body Mass Index (BMI) and Intermediate-Term Clinical Outcomes after Acute Coronary Syndromes: Observations from the SYMPHONY and 2 nd SYMPHONY Trials. <i>Am J Med</i> 2005; 118/9:981-990.
21.	Abdullah SM, Khera A, Das SR, Stanek HG, Canham RM, Chung AK, Morrow DA, Drazner MH, McGuire DK, de Lemos JA. Relation of Coronary Atherosclerosis Determined by Electron Beam Computed Tomography and Plasma Levels of N-terminal Pro-Brain Natriuretic Peptide in a Multiethnic Population-Based Sample (The Dallas Heart Study). <i>Am J Cardiol</i> 2005. 96: 1284-1289.
22.	de Lemos JA, Zirlik A, Schönbeck U, Varo N, Murphy SA, Khera A, McGuire DK, Stanek G, Lo HS, Nuzzo R, Morrow DA; Peshock R, Libby P. Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study. <i>Art Thromb Vasc Biol</i> 2005; 25: 2192-2196.
23.	Frazier CG, Shah SH, Newby LK, Bhapkar MV, McGuire DK, Weaver WD, Kristinsson A, Aylward PE, Klein WW, Sadowksi Z, Armstrong PW, for the SYMPHONY and 2 nd SYMPHONY Investigators. Prevalence and Management of Hypertension in Acute Coronary Syndrome Patients Varies by Sex. <i>Am Heart J</i> 2005; 150: 1260-1267.
24.	Robinson CR, Martin JL, Zhang L, Canham RM, Abdullah SM, Cigarroa JE, Hillis LD, Murphy

	SA, McGuire DK, de Lemos JA, Keeley EC. Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction. <i>Am J Cardiol</i> 2006; 97: 7-9.
25.	Khera A, de Lemos JA, Peshock RM, Lo H, Stanek HG, Murphy SA, Wians FH, Grundy SM, McGuire DK. Lack of an Independent Association Between C-Reactive Protein and Subclinical Atherosclerosis: The Dallas Heart Study. <i>Circulation</i> 2006;113 38-43.
26.	Das SR, Vaeth PAC, Stanek HG, de Lemos JA, Dobbins RL, McGuire DK. Under-diagnosis, Increased Coronary Calcium and Sub-optimal Cardiovascular Risk Modification Associated with Diabetes Mellitus in Dallas County:Observations from the Dallas Heart Study. <i>Am Heart J</i> 2006; 151: 1087-93.
27.	Church TS, Levine BD, McGuire DK, LaMonte M, Fitzgerald S, Cheng YJ, Kimball TE, Blair SN, Gibbons LW, Nichaman MZ. Coronary artery calcium score and risk of coronary heart disease events. <i>Atherosclerosis</i> 2007; 190: 224-31.
28.	Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, Wians F, Sabatine MS, Morrow DA, de Lemos JA. Prevalence and Determinants of Troponin T Elevation in the General Population. <i>Circulation</i> 2006; 113: 1958-65.
29.	Yan RT, Yan AT, Tan M, McGuire DK, Leiter L, Fitchett DH, Lauzon C, Lai K, Chow CM, Langer A, Goodman SG; for the Canadian Acute Coronary Syndrome Registry Investigators. Underutilization of Evidence-Based Treatment Partly Explains the Worse Clinical Outcome in Diabetic Patients with Acute Coronary Syndromes. <i>Am Heart J</i> 2006; 152: 676-683.
30.	Abrol R, Trost JC, Nguyen K, Cigarroa JE, Murphy SA, McGuire DK, Hillis LD, Keeley EC. Predictors of Coronary Artery Disease in Patients with Left Bundle Branch Block Undergoing Coronary Angiography. <i>Am J Cardiol</i> 2006; 98: 1307-10.
31.	Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK, Auchus RJ, de Lemos JA. Associations between Androgens, Estrogens and Natriuretic Peptides in Young Women: Observations from the Dallas Heart Study. <i>J Am Coll Cardiol</i> 2007; 49: 109-16.
32.	Abdullah SM, Khera A, Leonard D, Das SR, Canham RS, Kamath SA, Vega GL, Grundy SM, McGuire DK, de Lemos JA. Sex Differences in the Association between Leptin and CRP: Results from the Dallas Heart Study. <i>Atherosclerosis</i> 2007;195: 404-10.
33.	Abedin M, Omland T, Ueland T, Khera A, Aukrust P, , Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA. Relation of osteoprotegerin to coronary calcium and aortic plaque from The Dallas Heart Study. <i>Am J Cardiol</i> 2007; 99: 513-8.
34.	Philips B, de Lemos JA, Patel M, McGuire DK, Khera A. Relation of Family History of Myocardial Infarction and the Presence of Coronary Arterial Calcium in Various Age and Risk-Factor Groups. <i>Am J Cardiol</i> 2007; 99: 825-9.
35.	Jacobi JA, Parikh SV, McGuire DK, de Lemos JA, Murphy SA, Keeley EC. Racial Disparity in Clinical Outcomes Following Primary Percutaneous Coronary Intervention for ST

	Elevation Myocardial Infarction: Influence of Process of Care. <i>J Interv Cardiol</i> 2007, 20: 182-7.
36.	Patel MJ, de Lemos JA, Philips B, Murphy SA, Vaeth PC, McGuire DK, Khera A. Implications of Family History of Myocardial Infarction in Young Women. <i>Am Heart J</i> 2007; 154: 454-60.
37.	Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schönbeck U, Khera A, McGuire DK, Vega GL, Grundy SM, Libby P, de Lemos JA. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. <i>Arterioscler Thromb Vasc Biol</i> 2007; 27: 2043-9.
38.	Parikh SV, Abdullah SM, Keeley EC, Cigarroa JE, Addo TA, Warner JJ, Khera A, de Lemos JA, McGuire DK. Effect of Glucose-Insulin-Potassium (GIK) Infusion on Biomarkers of Cardiovascular Risk in ST Elevation Myocardial Infarction (STEMI): Insight into the Failure of GIK. <i>Diab Vasc Dis Res</i> 2007; 4: 222-225.
39.	Parikh SV, Jacobi JA, Chu E, Addo TA, Warner JJ, Delaney KA, McGuire DK, de Lemos JA, Cigarroa JE, Murphy SA, Keeley EC. Treatment Delay in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction: A Key Process Analysis of Patient and Program Factors. <i>Am Heart J</i> 2007;155:290-297.
40.	Yorio J, Viswanathan S, See R, Uchal L, McWhorter JA, Spencer N, Murphy SA, Khera A, de Lemos JA, McGuire DK. The Effect of a Disease Management Algorithm and Dedicated Post-Acute Coronary Syndrome Clinic on Achievement of Guideline Compliance: Results from the Parkland Acute Coronary Event Treatment (PACE-Rx) Study. <i>Journal of Investigative Medicine</i> , 2008; 56:15-25.
41.	Baber U, de Lemos JA, Khera A, McGuire DK, Omland T, Toto RD, Hedayati SS. Non-Traditional Cardiovascular Disease Risk Factors Attenuate the Relationship between Chronic Kidney Disease and Coronary Artery Calcification: Results from the Dallas Heart Study. <i>Kidney International</i> 2008; 73: 615-21.
42.	Brilakis ES, Khera A, McGuire DK, Banerjee S, Murphy SA, de Lemos JA. Influence of Race and Sex on Lipoprotein-Associated Phospholipase A2 Levels: Observations from the Dallas Heart Study. <i>Atherosclerosis</i> 2008;199:110-5.
43.	See R, Lindsey JB, Patel MJ, Ayers CR, Khera A, Grundy SM, McGuire DK, de Lemos JA. Application of the Screening for Heart Attack Prevention and Education (SHAPE) Guidelines to an Urban Population: Observations from the Dallas Heart Study. <i>Arch Int Med</i> 2008;168:1055-1062.
44.	Chen K, Lindsey JB, Khera A, de Lemos JA, Goyal A, Vega GL, Murphy SA, Grundy SM, McGuire DK. Independent Associations between Metabolic Syndrome, Diabetes Mellitus and Atherosclerosis: Observations from the Dallas Heart Study. <i>Diab Vasc Dis Res</i> . 2008; 5:96-101.
45.	McGuire DK, See R, Abdullah SM, Snell PG, McGavock JM, Szczepaniak LS. The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: Trial design and rationale. <i>Diab Vasc Dis Res</i> 2009; 6: 43-50.
46.	Das SR, Abdullah SM, Leonard D, Drazner MH, Khera A, McGuire DK, de Lemos JA. Impact

	of Renal Function on Circulating Levels of Natriuretic Peptides: Results from the Dallas Heart Study. <i>Am J Cardiol</i> 2008, 102: 1394-8.
47.	Rohatgi A, Ayers CR, Khera A, McGuire DK, Das SR, Matulevicius S, Timaran CH, Rosero EB, de Lemos JA. The Association Between Peptidoglycan Recognition Protein-1 and Coronary and Peripheral Atherosclerosis: Observations From the Dallas Heart Study. <i>Atherosclerosis</i> 2009; 230: 569-75.
48.	Brilakis ES, Khera A, Saeed B, Banerjee S, McGuire DK, Murphy SA, de Lemos JA. Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Coronary and Aortic Atherosclerosis: Findings From the Dallas Heart Study. <i>Clin Chem</i> 2008; 54: 1975-81.
49.	Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E, McCabe CH, Braunwald E, for the <u>M</u> etabolic <u>E</u> fficiency with <u>R</u> anolazine for <u>L</u> ess <u>I</u> schemia in <u>N</u> on-ST elevation acute coronary syndromes (MERLIN)-TIMI 36 Investigators. Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial. <i>Circulation</i> 2009; 119: 2032-9.
50.	McGavock JM, Hastings JL, Snell PG, McGuire DK, Pacini EL, Levine BD, Mitchell JH. A 40-Year Follow-Up of the Dallas Bed Rest and Training Study: The Effect of Age on the Cardiovascular Response to Exercise. <i>J Gerontol A Biol Sci Med Sci</i> . Feb 2009; 64: 293-299.
51.	de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Screening the Population for Left Ventricular Hypertrophy and Left Ventricular Systolic Dysfunction Using Natriuretic Peptides: Results from the Dallas Heart Study. <i>Am Heart J</i> . Apr 2009; 157: 746-753 e742.
52.	Patel MJ, de Lemos JA, McGuire DK, See R, Lindsey JB, Murphy SA, Grundy SM, Khera A. Evaluation of Coronary Artery Calcium Screening Strategies Focused on Moderately-High Risk Subjects: the Dallas Heart Study. <i>Am Heart J</i> 2009; 157: 1001-9.
53.	Parikh SV, Treichler DB, DePaola S, Sharpe J, Valdes M, Addo T, Das SR, McGuire DK, de Lemos JA, Keeley EC, Warner JJ, Holper E. Systems-Based Improvement in Door-to-Balloon Times at a Large, Urban, Teaching Hospital (A follow-up study from Parkland Health and Hospital System). <i>Circulation: Cardiovascular Quality and Outcomes</i> 2009; 2:116-22.
54.	Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK. Association Between Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) and Risk for Atherosclerosis: Observations from the Dallas Heart Study. <i>Diabetes Care</i> 2009; 32:1218-1220.
55.	Rohatgi A, Owens AW, Khera A, Ayers CR, Banks K, Das SR, Berry JD, McGuire DK, de Lemos JA. Differential Associations between Soluble Cellular Adhesion Molecules and Atherosclerosis in the Dallas Heart Study: a Distinct Role for Soluble Endothelial Cell-Selective Adhesion Molecule. <i>Arterioscler Thromb Vasc Biol</i> 2009; 29:1684-1690.
56.	Davidson MH, Maki KC, Dicklin MR, Feinstein SB, Witchger MS, Bell M, McGuire DK, Provost JC, Liker H, Aviram M. Effects of Consumption of Pomegranate Juice on Carotid

	Intima-Media Thickness in Men and Women at Moderate Risk for Coronary Heart Disease. <i>Am J Cardiol</i> 2009; 104:936-42.
57.	Khera A, Vega GL, Das SR, Ayers C, McGuire DK, Grundy SM, de Lemos JA. Sex Differences in the Relationship Between C-Reactive Protein and Body Fat. <i>J Clin Endocrinol and Metab</i> 2009; 94:3251-8.
58.	Petersen JL, Yow E, Al-Jaroudi W, Shaw L, Goyal A, McGuire DK, Peterson ED, and Harrington RA. Metabolic Syndrome is Not Associated with Increased Mortality or Cardiovascular Risk in Patients With a New Diagnosis of Coronary Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> 2010; 3:165-72.
59.	Castillo L, Rohatgi A, Ayers CR, Owens AW, Das SR, Khera A, McGuire DK, de Lemos JA. Associations of Four Circulating Chemokines With Multiple Atherosclerosis Phenotypes in a Large Population-Based Sample: Results From the Dallas Heart Study. <i>J Interferon Cytokine Res</i> 2010; 30:339-47.
60.	Marso SP, Kennedy KF, House JA, McGuire, DK. The Effect of Tight Glycemic Control On All-Cause Mortality, Myocardial Infarction and Stroke in Persons with Type 2 Diabetes Mellitus. <i>Diab Vasc Dis Res</i> 2010; 7:119-30.
61.	Gruntmanis U, Fordann S, Ghayee HK, Abdullah SM, See R, Ayers CR, McGuire DK. The Peroxisome Proliferator-Activated Receptor- γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled Trial. <i>Calcified Tissue International</i> 2010; 86:343-9.
62.	McGuire DK, Abdullah SM, See R, Snell PG, McGavock J, Szczepaniak LS, Ayers CR, Drazner MH, Khera A, de Lemos JA. Randomized Comparison of the Effects of Rosiglitazone versus Placebo on Peak Integrated Cardiovascular Performance, Cardiac Structure, and Function. <i>Eur Heart J.</i> 2010; 31: 2262-70.
63.	Powell TM, de Lemos JA, Banks K, Ayers CR, Rohatgi A, Khera A, McGuire DK, Berry JD, Albert MA, Vega GL, Grundy SM, Das SR. Body size misperception: a novel determinant in the obesity epidemic. <i>Arch Intern Med.</i> 2010; 170: 1695-7.
64.	Owens AW, Matulevicius S, Rohatgi A, Berry JD, Ayers CR, Khera A, Das SR, McGuire DK, de Lemos JA. Circulating Lymphotoxin Beta Receptor and Atherosclerosis: Observations from the Dallas Heart Study. <i>Atherosclerosis</i> 2010; 212: 601-6.
65.	de Lemos JA Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, MD, Berry JD, Das SR, Morrow DA, McGuire DK. A Highly Sensitive Assay for Cardiac Troponin T in the General Population. <i>JAMA.</i> 2010; 304:2503-12.
66.	Carson AP, Fox CS, McGuire DK, Levitan EB, Laclaustra M, Mann DV, Muntner P. Low Hemoglobin A1c and Risk of All-Cause Mortality among U.S. Adults with and without Diabetes. <i>Circ Cardiovasc Qual Outcomes.</i> 2010; 3:661-7.
67.	Banks K, Puttagunta D, Murphy S, Lo M, McGuire DK, de Lemos JA, Chang AY, Grundy SM,

	Khera A. Characteristics, Vascular Function, and Inflammation in Women with Angina in the Absence of Coronary Atherosclerosis: The Dallas Heart Study. <i>JACC Cardiovasc Imaging</i> . 2011;4: 65-73.
68.	Holper EM, Abbott JD, Mulukutla S, Vlachos H, Selzer F, McGuire DK, Faxon DP, Laskey W, Srinivas VS, Marroquin OC, Jacobs AK. Temporal changes in the outcomes of patients with diabetes mellitus undergoing percutaneous coronary intervention in the National Heart, Lung, and Blood Institute dynamic registry. <i>Am Heart J</i> . 2011;161:397-403 e1
69.	Britton KA, Agarwal V, Chen AY, Alexander KP, Amsterdam E, Fraulo E, Muntner P, Thomas L, McGuire DK, Wiviott SD, Roe MT, Schubart UK, Fox CS. No Association between Hemoglobin A1c and In-Hospital Mortality in Patients with Diabetes and Acute Myocardial Infarction. <i>Am Heart J</i> . 2011; 161: 657-63 e1.
70.	Nguyen AB, Rohatgi A, Garcia CK, Ayers CR, Das SR, Lakoski SG, Berry JD, Khera A, McGuire DK, de Lemos JA. Interactions Between Smoking, Pulmonary Surfactant Protein B, and Atherosclerosis in the General Population: The Dallas Heart Study. <i>Arterioscler Thromb Vasc Biol</i> . 2011, 31: 2136-43.
71.	Narang N, Armstead SI, Stream A, Abdullah SM, See R, Snell PG, McGavock J, Ayers CR, Gore MO, Khera A, de Lemos JA, McGuire DK. Assessment of Cardiac Structure and Function in Patients without and with Peripheral Oedema during Rosiglitazone Treatment. <i>Diab Vasc Dis Res</i> . 2011;8:101-8.
72.	Hamilton MP, Ayers CR, Gore MO, Wu X, McGuire DK, and Scherer PE. Adiponectin and Cardiovascular Risk Profile in Patients with Type 2 Diabetes Mellitus: Parameters Associated with Adiponectin Complex Distribution. <i>Diab Vasc Dis Res</i> . 2011; 8:190-4.
73.	Powell-Wiley TM, Ayers CR, Banks-Richard K, Berry JD, Khera A, Lakoski SG, McGuire DK, de Lemos JA, Das SR. Disparities in Counseling for Lifestyle Modification among Obese Adults: Insights from the Dallas Heart Study. <i>Obesity</i> 2011; <i>In Press</i> .
74.	Grodin JL, Powell TM, Ayers CR, Kumar DS, Rohatgi A, McGuire DK, Khera A, de Lemos JA, Das SR. Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: from the Dallas Heart Study. <i>Vasc Med</i> . 2011, <i>In Press</i>
75.	Narang N, Gore MO, Snell PG, Ayers CR, Lorenzo S, Carrick-Ranson G, Babb TG, Levine BD, Khera A, de Lemos JA, McGuire DK. Accuracy of Estimating Resting Oxygen Uptake and Implications for Hemodynamic Assessment. <i>Am J Cardiol</i> . 2011, <i>In Press</i> .
76.	McGavock J, Szczepaniak LS, Abdullah SM, See R, Snell PG, Ayers CR, Mark H, Drazner MH, Khera A, de Lemos JA, McGuire DK. The effects of rosiglitazone on myocardial triglyceride content in humans: A randomized, placebo-controlled trial using in vivo proton magnetic resonance spectroscopy. <i>Diab Vasc Dis Res</i> . 2011, <i>In Press</i> .
77.	Stolker JM, Spertus JA, McGuire DK, Lind M, Tang F, Jones PG, Inzucchi SE, Rathore SS, Maddox TM, Masoudi FA, Kosiborod M. Relationship Between Glycosylated Hemoglobin Assessment and Glucose Therapy Intensification in Patients With Diabetes Hospitalized for

	Acute Myocardial Infarction. <i>Diabetes Care</i> 2012, <i>In Press</i>
--	---

Reviews, Chapters, Monographs and Editorials

1.	Califf RM, McGuire DK, Feinglos MA. Caring for the patient with diabetes and myocardial infarction. In Califf, RM, ed. <i>New Standards of AMI Care. Part V: Reperfusion of Special Populations</i> . New York: Excerpta Medica, Inc, 1998:13-25.
2.	McGuire DK, Granger CB, Califf RM, <i>editors</i> . Diabetes and Cardiovascular Disease: Current opinions and future directions-Proceedings of a symposium. <i>Am Heart J</i> 1999; 138: S327-S416.
3.	McGuire DK, Califf RM. Diabetes and Cardiovascular Disease: Current opinions and future directions-Introduction. <i>Am Heart J</i> 1999; 138: S327-329.
4.	Abraira C, McGuire DK. Intensive insulin therapy in patients with type 2 diabetes: Implications of the Veterans Affairs (VACSDM) feasibility trial. <i>Am Heart J</i> 1999; 138: S360-S365.
5.	McGuire DK, Granger CB. Diabetes and ischemic heart disease. <i>Am Heart J</i> 1999; 138: S366-S375.
6.	Malmberg K, McGuire DK. Diabetes and acute myocardial infarction: The role of insulin therapy. <i>Am Heart J</i> 1999; 138: S381-S386.
7.	Diaz R, McGuire DK. Optimal dosage of insulin and glucose in Glucose-Insulin-Potassium treatment of acute myocardial infarction remains to be established. <i>Circulation</i> 1999; 100: e106-e107.
8.	McGuire DK, Hudson MP, East MA, Dyke CD, Battle J, Bahit MC, Al-Khatib SM, Alexander JH. AHJ at the Meetings: Highlights from the American Heart Association 72 nd Scientific Sessions November 6 to 10, 1999. <i>Am Heart J</i> 2000; 139:359-370.
9.	McGuire, DK. The Influence of Proteinuria on Long-term Outcome Among Patients with Diabetes: The evidence continues to accumulate. <i>Am Heart J</i> 2000; 139:934-935.
10.	McGuire DK, Newby LK. Oral glycoprotein IIb/IIIa antagonists: New insights from the SYMPHONY Trial. <i>Journal of Thrombosis and Thrombolysis</i> 2000;10:111-120.
11.	McGuire DK, O'Shea JC, Dyke CK, Kandzari D, East MA, Tolleson TR. Highlights from the American College of Cardiology 49 th Annual Scientific Sessions: March 12 to 15, 2000. <i>Am Heart J</i> 2000; 140:181-188.
12.	Newby LK, McGuire DK. Oral platelet glycoprotein IIb/IIIa inhibition. <i>Curr Cardiol Rep</i> 2000; 2:372-377.
13.	McGuire DK, O'Shea JC, Dyke CK, Velazquez EJ, Hudson MP. Highlights from the XXII Congress of the European Society of Cardiology: August 26 to 30, 2000. <i>Am Heart J</i> 2001; 141:164-172.

14.	Sanchez CD, McGuire DK. Diabetes mellitus and clinical outcomes following acute coronary syndromes. <i>Cardiology Reviews</i> 2001;18:10-14.
15.	O'Shea JC, Bahit C, Tolleson TR, Cabell C, Dyke CK, Kaul A, McGuire DK, East MA. Highlights from the American Heart Association Annual Scientific Sessions 2000: November 12 to 15, 2000. <i>Am Heart J</i> 2001; 141: 306-318.
16.	Bahit MC, Cabell CH, Dyke CK, Felker GM, Kaul P, McGuire DK, Reddan D, East M. Highlights from the American College of Cardiology 49 th Annual Scientific Sessions: March 18 to 21, 2001. <i>Am Heart J</i> 2001; 142:363-74.
17.	Patel MR, McGuire DK. Pounds of prevention: Obesity therapy. <i>Am Heart J</i> 2001; 142:388-90.
18.	Abedin M, McGuire DK. Don't miss this opportunity: Diagnosing diabetes. <i>Am Heart J</i> 2003; 145:195-7.
19.	de Lemos JA, McGuire DK, Drazner MH. B-type Natriuretic Peptide (BNP) in Cardiovascular Disease. <i>Lancet</i> 2003; 362: 316-22.
20.	Rao SV, McGuire DK. Epidemiology of Diabetes Mellitus and Cardiovascular Disease <i>in</i> The Textbook of Diabetes Mellitus and Cardiovascular Disease. David Stern and Steven P. Marso, editors. Lippincott Williams & Wilkins, Philadelphia, 2003.
21.	Keebler ME, McGuire DK. Subclinical Diabetes: Is it really sub-clinical? <i>Am Heart J</i> 2003;146:210-212
22.	McGuire DK, Newby LK, Biswas M, Hochman JS. The Elderly, Woman, and Patient with Diabetes <i>in</i> Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease. Pierre Theroux, Editor. Harcourt Health Sciences, 2003.
23.	Petersen JL, McGuire DK, Harrington RA. Advances and continued controversy in revascularization for coronary artery disease in patients with diabetes mellitus. <i>Current Diabetes Reports</i> 2003; 3:351-355.
24.	McGuire DK, Rao SV. Epidemiology of Diabetes and Cardiovascular Disease <i>in</i> The Handbook of Diabetes and Cardiovascular Disease. Steven P. Marso, editor. Remedica Publishing, London UK, 2003.
25.	Martin JL, McGuire DK. Influence of BARI on revascularization in patients with diabetes. <i>Cardiology Reviews</i> 2004; 21: 14-18.
26.	Berry J, Keebler ME, McGuire DK. Diabetes and Cardiovascular Disease: Pandora's Box has been Opened. <i>Herz</i> 2004; 29: 456-462.
27.	Gnaim CI, McGuire DK. Glucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: What goes around comes around. <i>Am Heart J</i> 2004; 148:924-930.

28.	Petersen JL, McGuire DK. Implications for Cardiovascular Risk and Management of Impaired Glucose Tolerance and Impaired Fasting Glucose. <i>Diab Vasc Dis Res</i> 2005; 2: 9-15.
29.	Patel CB, Wyne K, McGuire DK. Thiazolidinediones, Peripheral Edema and CHF: What is the evidence? <i>Diab Vasc Dis Res</i> , 2005; 2: 61-66.
30.	Khera A, McGuire DK. Management of Diabetic Dyslipidemia: Need for Reappraisal of the Goals. <i>Am J of Cardiovascular Drugs</i> , 2005; 2: 83-91.
31.	McGuire DK, Rutherford JD. Risk factors-Diabetes and CHD. ACC SAP Version 6, Richard P. Lewis, editor; 2005. pp. 10.22-10.30.
32.	Patel M, McGuire DK. How Aggressive Should Lipid Lowering Be Among Patients With Acute Coronary Syndromes? <i>Current Cardiology Reports</i> 2005; 7: 283-287.
33.	Grant PJ, McGuire DK. The Metabolic Syndrome: 'To be or not to be, that is the question. <i>Diabetic Medicine</i> 2006; 23: 16-18.
34.	Friedewald VE, Leiter LA, McGuire DK, Nesto RW, Roberts WC. The Editor's Roundtable: Diabetes Mellitus and Coronary Heart Disease. <i>Am J Cardiol</i> 2006; 98:842-856.
35.	Patel CB, de Lemos JA, Wyne K, McGuire DK. Thiazolidinediones and Atherosclerosis: Pleiotropic effects of PPAR γ agonism. <i>Diab Vasc Dis Res</i> 2006; 3: 65-71.
36.	Stancoven A, McGuire DK. Preventing Macrovascular Complications in Type 2 Diabetes Mellitus: Glucose Control and Beyond. <i>Am J Cardiol</i> 2007; 99 (supp): 5H-11H.
37.	McGuire DK. Rosiglitazone and cardiovascular disease: An epidemiologist perspective. <i>Diab Vasc Dis Res</i> 2007;4: 77-79.
38.	McGuire DK, Inzucchi SE. New Drugs for the Treatment of Diabetes: Thiazolidinediones and their Evolving Cardiovascular Implications. <i>Circulation</i> 2008; 117: 440-449.
39.	Inzucchi SE, McGuire DK. New Drugs for the Treatment of Diabetes: Incretin-based Therapy and Beyond. <i>Circulation</i> 2008; 117: 574-584.
40.	Petersen JL, McGuire DK. Management of Coronary Artery Disease in Type 2 Diabetes Mellitus in Contemporary Endocrinology: Type 2 Diabetes Mellitus: An Evidence-based Approach to Practical Management, edited by Feinglos MN and Bethel MA. Humana Press, Totowa NJ, 2008.
41.	McGuire DK, Wyne KL. Combating Childhood Type 2 Diabetes Mellitus: It Will Take a Village. <i>Diab Vasc Dis Res</i> 2007; 4: 283-284
42.	McGuire DK, <i>Guest Editor</i> . Special Issue on Childhood Type 2 Diabetes. <i>Diab Vasc Dis Res</i> 2007, 4: 283-311
43.	McGuire DK, Winterfield JR, Rytlewski JA, Ferrannini E. Blocking the Renin-Angiotensin-Aldosterone System to Prevent Diabetes Mellitus. <i>Diab Vasc Dis Res</i> 2008; 5:59-66.

44.	Rohatgi A, McGuire DK. Effects of the Thiazolidinedione Medications on Micro- and Macrovascular Complications in Patients with Diabetes – Update 2008. <i>Cardiovasc Drugs Ther</i> 2008; 22:233-40.
45.	Saunders J, Mathewkutty S, Drazner M, McGuire DK. Cardiomyopathy in Type 2 Diabetes: Update on Pathophysiologic Mechanisms. <i>Herz</i> 2008; 33: 184-190.
46.	Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for Advanced Glycation End Products (RAGE) and Soluble RAGE (sRAGE): Cardiovascular Implications. <i>Diab Vasc Dis Res</i> 2009; 6: 7-14.
47.	Gore MO, McGuire DK. The 10-year Post Trial Follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): Cardiovascular Observations in Context. <i>Diab Vasc Dis Res</i> 2009; 6: 53-55.
48.	McGuire DK, Inzucchi SE. Cardiovascular Considerations for the Use of Thiazolidinedione Medications, in <i>Harrison's Online Textbook of Internal Medicine, 17e</i> , edited by Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson L, and Loscalzo J, 2009. http://www.accessmedicine.com/updatesContent.aspx?aID=1001451&searchStr=thiazolidinedione (Accessed 3/9/2010)
49.	Mathewkutty S, McGuire DK. Platelet perturbations in Diabetes: Implications for Cardiovascular Disease Risk and Treatment. <i>Expert Reviews in Cardiovascular Therapy</i> 2009;7:541-9.
50.	Gore MO, McGuire DK. Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs. <i>Current Cardiology Reports</i> 2009; 11: 258-263.
51.	Gore MO, Masoudi FA, McGuire DK. Diabetes Mellitus in Patients with Myocardial Infarction Complicated by Heart Failure: A "Low Ejection Fraction" Equivalent? <i>Eur J Heart Failure</i> 2010; 12: 1156-8.
52.	Clark A, Rivera SM, Sheppard D, McGuire DK, McPhaul MJ. "Writing Informed Consent Documents and Obtaining Informed Consent," in <i>Clinical Research: From Proposal to Implementation, 1st Ed.</i> , edited by Michael J. McPhaul and Robert D. Toto. Philadelphia, Lippincott Williams & Wilkins, 2010.
53.	McGuire DK, Gore MO, Masoudi FA. Diabetes and heart failure in patients with coronary disease: Separating Markers from Mediators. <i>Diabetes Care</i> 2010; 33: 2120-2.
54.	McGuire DK. The Cardiovascular Quandary, in <i>Hypoglycemia in Type 2 Diabetes: Current Controversies and Changing Practice</i> edited by Henry RR. London, The Royal Society of Medicine Press Limited, 2010.
55.	Gore MO, Inzucchi S, McGuire DK. Diabetes and Cardiovascular Disease, in <i>Prevention of Cardiovascular Disease: A Companion to Braunwald's Heart Disease</i> edited by Blumenthal RS, Foody JM, and Wong ND. Saunders, an imprint of Elsevier, Inc. Philadelphia, PA. 1 st Edition, 2010.

56.	Kosiborod M, McGuire DK. Glucose Lowering Targets for Patients with Cardiovascular Disease: Focus on inpatient management of patients with acute coronary syndromes. <i>Circulation</i> 2010;122: 2736-44.
57.	McGuire DK. Diabetes and the cardiovascular system, in Braunwald's Heart Disease: A textbook of cardiovascular medicine 9E, edited by Libby P, Bonow RO, Mann DL, Zipes DP. Philadelphia, Saunders Elsevier, 2010.
58.	Gore MO, McGuire DK. Resolving Drug Effects from Class Effects among Drugs for Type 2 Diabetes Mellitus: More support for cardiovascular outcomes assessments. <i>Eur Heart J</i> 2011; 32:1832-4.
59.	Goyal A, Kosiborod M, McGuire DK, Garber AJ. A1C : Glucose management in type 2 diabetes mellitus. American College of Cardiology Foundation Diabetes Self-Assessment Program. Washington DC: American College of Cardiology Foundation, 2011.
60.	de Lemos JA, McGuire DK. Biomarkers in clinical trials: can we move from fortune telling to disease profiling? <i>Circ</i> 2011; 124: 663-665.
61.	Gore MO, Kosiborod M, McGuire DK. Hyperglycemia in Acute Coronary Syndromes, in Evidence-base Management of Diabetes, edited by Vora J and Buse JB. tfm Publishing Ltd, Shropshire UK, 2010. <i>In Press</i>
62.	Hall HM, Banerjee S, McGuire DK. Variability of clopidogrel response in patients with type 2 diabetes mellitus. <i>Diab Vasc Dis Res</i> 2011, <i>In Press</i> .
63.	Gore MO, McGuire DK. Drugs for Type 2 Diabetes Mellitus: The Imperative for Cardiovascular Outcome Assessment. <i>Diab Vasc Dis Res</i> 2012, <i>In Press</i> .

Books/Textbooks

1.	American College of Cardiology Foundation Diabetes Self-Assessment Program, edited by McGuire DK and Sperling L. Washington DC : American College of Cardiology Foundation, 2011.
----	---

Case Reports

1.	ElMunzer BJ, Sallach SM, McGuire DK. Case Report: Cardiac Chagas' Disease masquerading as an acute MI. <i>Cardiology in Review</i> 2004;12: 69-72.
2.	Martin JL, McGuire DK. Case Report: Coronary artery bypass graft surgery for a diabetic patient. <i>Cardiology Reviews</i> 2004; 21: 19.
3.	McCullum DL, Greene J, McGuire DK. Severe bradycardia after initiation of bupropion therapy: A possible drug-drug interaction with metoprolol. <i>Cardiovascular Drugs and Therapy</i> , 2004; 18:329-30.

4.	Aslam MK, Gnaim C, Kutnick J, Kowal RC, McGuire DK. Syndrome of inappropriate anti-diuretic hormone secretion induced by amiodarone therapy. <i>PACE</i> 2004; 27:831-832.
5.	Dorfman T, Canales J, Farukhi I, McGuire DK. Sarcoidosis Masquerading as an Acute Coronary Syndrome. <i>Cardiology in Review</i> 2005; 13:256-259.
6.	Cho MN, Mehta SK, Matulevicius S, Weinstein D, Wait MA, McGuire DK. Differentiating True versus Pseudo Left Ventricular Aneurysm: A Case Report and Review of Diagnostic Strategies. <i>Cardiology in Review</i> 2006, 14: e27-e30.
7.	Parikh SV, Memon N, Echols M, Shah J, McGuire DK, Keeley EC. Purulent Pericarditis: A Case Series and Review of the Literature. <i>Medicine</i> 2009; 88: 52-65.

Letters to the Editor

1.	de Lemos JA, McGuire DK. Aspirin, clopidogrel, or both for secondary prevention of coronary disease (Letter). <i>N Eng J Med</i> 2003; 348: 560-3.
2.	Drazner MH, McGuire DK, de Lemos JA. Nesiritide in acute heart failure (letter). <i>Lancet</i> 2003; 362: 998-999.
3.	McGuire DK, Newby LK. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. (Letter) <i>Am Heart J</i> 2004; 148:e28.
4.	Inzucchi SE, Masoudi FA, McGuire DK. Metformin in Heart Failure. (Letter) <i>Diabetes Care</i> 2007, 30:e129.
5.	Inzucchi SE, Masoudi FA, McGuire DK. Metformin Therapy in Patients with Type 2 Diabetes Complicated by Heart Failure. (Letter) <i>Am Heart J</i> 2007;154:e45.
6.	McGuire DK, Aguilar D. Effects of torcetrapib on glucose metabolism (Letter). <i>Circulation</i> 2011, <i>In Press</i> .

Proceedings of Meetings

1.	
2.	

Clinical Practice Guidelines

1.	Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, Garvey WT, Gavin JR 3rd, Grunberger G, Horton ES, Jellinger PS, Jones KL, Lebovitz H, Levy P, McGuire DK, Moghissi ES, Nesto RW. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. <i>Endocr Pract</i> 2008;14:933-46.
----	---

--	--

Non-peer reviewed scientific or medical publications/materials in print or other media

1	McGuire DK. Diabetes and Cardiovascular Disease: Evidence-Based Therapy. <i>Resident and Staff Physician</i> 2000; 46:19-31.
2	McGuire DK. Glucose Control in Acute Coronary Syndromes: Making a Hasty Retreat. Cardiosource Web Site, American College of Cardiology Foundation. Available at http://www.cardiosource.com/expertopinions/hottopics/article.asp?paperID=343 . Accessed June 15, 2009.
3	Khera A, McGuire DK. Lipid Management in Patients with Diabetes: LDL Lowering, Then What? Cardiosource Web Site, American College of Cardiology Foundation. Available at http://www.cardiosource.com/expertopinions/hottopics/article.asp?paperID=379 . Accessed February 4, 2010.
4	Gore MO, McGuire DK. Aspirin for Primary Prevention of Cardiovascular Events in People with Diabetes: The more we know, the more we don't know. Available in: American Heart Association Learning Library. http://pt.wkhealth.com/pt/re/chf/addcontent.14201438.htm;jsessionid=MJsLLb0SG76nLYVrPVwTbjX6vpx18tFHZQkblQWvxf0h8mlXZbFP!215724456!181195629!8091!-1 . Pub 5/27/2010.

In Review:

Banks K, Berry JD, Das SR, Rohatgi A, Ayers CR, McGuire DK, Grundy SM, de Lemos JA, Khera A. The association between an optimal risk factor profile and subclinical atherosclerosis in a multiethnic population: results from the Dallas Heart Study. *In Review*.

Gupta NK, de Lemos JA, Ayers CR, Abdullah S, McGuire DK, Khera A. The Relationship between C-Reactive Protein and Atherosclerosis Differs Based on Body Mass Index: The Dallas Heart Study. *In Review*

Venkitachalam L, McGuire DK, Gosch K, Lipska K, Inzucchi SE, Lind M, Goyal A, Spertus JA, Masoudi FA, Jones PG, Kosiborod M. Temporal trends and hospital variation in the management of hyperglycemia among patients with acute myocardial infarction in the United States. *In Review*.

Gore MO, Patel MJ, Kosiborod M, Parsons LS, Khera A, de Lemos JA, Rogers WJ, Peterson ED, Canto JC, McGuire DK, for the National Registry of Myocardial Infarction Investigators. Diabetes Mellitus and Survival Following Myocardial Infarction, 1994-2006. *In Review*

